No abstract available.
Genetic Therapy* ; Oligonucleotides*

A series of modified oligonucleotides containing P=S backbone and a six-membered azasugar (6-AZS) were synthesized and tested for their ability to inhibit human immunodeficiency virus (HIV) in vitro without the aid of any transfecting agents. While P=S oligonucleotides with natural nucleotides had little anti-HIV-1 activity, six-membered azasugar nucleotide (6-AZN)-containing P=S oligonucleotides (AZPSON) potently inhibited the HIV-1/SHIV production and syncytium formation in vitro (EC50 = 0.02~0.2 micro M) without cytotoxicity up to 100 micro M. AZPSONs are enzymatically stable over 6 days in culture supernatant. Phosphodiester (P=O) backbone only or mixed backbone (P=O and P=S) oligonucleotides that contain 6-AZN did not exhibit anti-HIV-1 activity. The anti-HIV-1 capacity of AZPSON seems to depend on the number and/or distribution patterns of 6-AZN in the oligonucleotides. The oligomer 2198, most effective for anti-HIV-1 activity among the AZPSONs, was much more effective than ddI or ddC in anti-HIV activity. Particularly noteworthy is that the anti-HIV-1 activity of AZPSON-2198 was better than AZT in the long-lasting efficacy after a single treatment.
Giant Cells ; HIV ; HIV-1 ; Nucleotides ; Oligonucleotides ; Phosphorothioate Oligonucleotides*

Bar-code (tag) microarrays of yeast gene-deletion collections facilitate the systematic identification of genes required for growth in any condition of interest. Anti-sense strands of amplified bar-codes hybridize with ~10,000 (5,000 each for up- and down-tags) different kinds of sense-strand probes on an array. In this study, we optimized the hybridization processes of an array for fission yeast. Compared to the first version of the array (11 µm, 100K) consisting of three sectors with probe pairs (perfect match and mismatch), the second version (11 µm, 48K) could represent ~10,000 up-/down-tags in quadruplicate along with 1,508 negative controls in quadruplicate and a single set of 1,000 unique negative controls at random dispersed positions without mismatch pairs. For PCR, the optimal annealing temperature (maximizing yield and minimizing extra bands) was 58℃ for both tags. Intriguingly, up-tags required 3× higher amounts of blocking oligonucleotides than down-tags. A 1:1 mix ratio between up- and down-tags was satisfactory. A lower temperature (25℃) was optimal for cultivation instead of a normal temperature (30℃) because of extra temperature-sensitive mutants in a subset of the deletion library. Activation of frozen pooled cells for >1 day showed better resolution of intensity than no activation. A tag intensity analysis showed that tag(s) of 4,316 of the 4,526 strains tested were represented at least once; 3,706 strains were represented by both tags, 4,072 strains by up-tags only, and 3,950 strains by down-tags only. The results indicate that this microarray will be a powerful analytical platform for elucidating currently unknown gene functions.
Oligonucleotides ; Polymerase Chain Reaction ; Schizosaccharomyces ; Yeasts

Despite advances in neurosurgery, radiation, and chemotherapy, the prognosis of patients with malignant brain tumors still remains grim. Considerable efforts have been made to develop new therapeutic strategies for malignant brain tumors. One of the promising new therapies for brain tumors is an intervention at molecular level, and several molecular approaches have been shown to have in vitro and in vivo activities. These include the use of retroviral vectors, herpes simplex viruses, adenoviral vectors in gene transfer, and antisense vectors and oligonucleotides. Preclinical studies of retroviral vector have already been extended to clinical trials, clearly demonstrating the clinical potential of these molecular therapies. Here, I discuss the current status of molecular therapy for brain tumors together with future directions for its development.
Brain Neoplasms* ; Brain* ; Drug Therapy ; Humans ; Neurosurgery ; Oligonucleotides ; Oligonucleotides, Antisense* ; Prognosis ; Simplexvirus ; Zidovudine

The major issue in the development of nucleic acid based therapeutics is the inefficient delivery of these agents into cells. We prepared cholesterol conjugated spermine and evaluated its usefulness as a delivery modality for antisense oligonucleotides in HeLa-Luc cells. A 2'-O-methyl antisense oligonucleotide sequence, designed to correct splicing at an aberrant intron inserted into a normal luciferase reporter gene, was used for complex formation with cholesterol conjugated spermine. Effective delivery of this antisense agent into nucleus would results in the expression of a luciferasereporter gene product. The cholesterol-spermine formed stable complexes with the antisense oligonucleotide and showed modest delivery activity. Furthermore, this delivery activity was maintained even in the presence of serum proteins, mimicking in vivo conditions. Cholesterol-spermine thus has potential as a delivery system for antisense oligonucleotides into cells.
Blood Proteins ; Cholesterol* ; Genes, Reporter ; Introns ; Luciferases ; Oligonucleotides, Antisense ; Spermine*

SELEX technology (Systematic Evolution of Ligand by Exponential Enrichment) is a new in vitro screening technology appeared and developed in the past 20 years. SELEX integrate library technology and screening techniques, screening a nucleic acid molecule from nucleic acid library by ligand-aptamer interaction. Similar to the antibodies, aptamers bind with the specific target substance. SELEX screening technology develops rapidly, and aptamer have been widely applied in biomedical field. This article briefly-overviewed the progress and its applications of SELEX technology in recent years.
Animals ; Gene Library ; Humans ; Oligonucleotides ; genetics ; SELEX Aptamer Technique ; methods

Oligonucleotide drugs have the characteristics of targeting, modifiability and high biosafety. Recent studies have shown that oligonucleotide can be used to make biosensors, vaccine adjuvants, and has the functions of inhibiting alveolar bone resorption, promoting jaw and alveolar bone regeneration, anti-tumor, destroying plaque biofilm, and precise control of drug release. Therefore, it has a broad application prospect in the field of stomatology. This article reviews the classification, action mechanism and research status of oligonucleotide in stomatology. The aim is to provide ideas for further research and application of oligonucleotide.
Humans ; Alveolar Bone Loss ; Biofilms ; Bone Regeneration ; Oligonucleotides ; Oral Medicine

OBJECTIVETo test the efficiency of transfecting (99)Tc(m)-labeled anti-miR208b oligonucleotide into early hypertrophic cardiac myocytes in vitro.

METHODSThe anti-oligonucleotide targeting miR208b (AMO) was synthesized and modified with LNA followed by conjugation with N-hydroxysuccinimidyl S-acetyl-meraptoacetyl triglycine (NHS-MAG3) and radiolabeling with (99)Tc(m). NHS-MAG3-LNA-AMO and labeled AMO were purified with Sep-Pak C18 column chromatography, and the former was examined for UV absorption at the 260 nm using Gene Quant DNA/RNA calculator. The labeling efficiency, radiochemical purity, stability and molecular hybridization activity were analyzed. An angiotensin II-induced cell model of hypertrophic cardiac myocytes was transfected with (99)Tc(m)-NHS-MAG3-LNA-AMO via liposome, and the relative expression of miRNA208b and retention ratio of the labeled AMO in early hypertrophic cells were determined.

RESULTSThe labeling efficiency and radiochemical purity of the labeled AMO after purification exceeded 84% and 86%, respectively. The radio- chemical purities of the labeled AMO incubated in serum and normal saline for 12 h were both higher than 80%, and the labeled AMO showed a capacity to hybridize with the target gene. In the hypertrophic model of cardiac myocytes, the retention ratio of labeled AMO at 6 h was higher than 20%.

CONCLUSIONThe (99)Tc(m)-labeled antisense probe can be efficiently transfected into hypertrophic cardiac myocytes in vitro, which provides an experimental basis for subsequent radionuclide imaging studies.

Humans ; Isotope Labeling ; Liposomes ; MicroRNAs ; genetics ; Myocytes, Cardiac ; Oligonucleotides ; Oligonucleotides, Antisense ; Oligopeptides ; Radiopharmaceuticals ; Silicon Dioxide ; Succinimides ; Transfection

Human T-cell lymphotrophic virus type I (HTLV-I) is a causative agent of adult T-cell leukemia (ATL). The viral transcriptional activator Tax encoded by the HTLV-I genome is thought to play critical roles in the activation of nuclear factor kappaB(NF-kappaB) as well as in the transformation of human T lymphocytes and the induction of tumor and leukemia. In this report, we suggest that RelA subunit of NF-kappaB might play an important role in Tax-induced p53 inactivation. Using antisense oligonucleotides, the ability of Tax inhibiting p53 transactivation was blocked by RelA, but not p50 or c-rel, antisense oligonucleotides in C81 HTLV-1-transfected cell line. The inability of p50 or c-rel antisense oligonucleotides in blocking the Tax-mediated inhibition of p53 function was not due lack of activity, since NF-kappaB activation was specifically blocked by these oligonucleotides. Also, we demonstrate by using co-immunoprecipitation assays that p53 interacts with RelA in HTLV-I transformed cells and their binding became stronger by the overexpression of Tax in 293T cells. These results suggest the possibility that the physical interaction between p53 and RelA correlates with Tax-induced p53 inhibition.
Cell Line ; Genome ; Human T-lymphotropic virus 1 ; Humans* ; Immunoprecipitation ; Leukemia ; Leukemia-Lymphoma, Adult T-Cell ; NF-kappa B* ; Oligonucleotides ; Oligonucleotides, Antisense ; T-Lymphocytes* ; Taxes ; Transcriptional Activation

To study the pharmacokinetics of cantide, an antisense oligonucleotide, and its metabolites after iv gtt administration in rhesus monkeys, a dual solid phase extraction pretreatment method coupling with non-gel sieving capillary electrophoresis analysis method was used for determination of cantide and its metabolites in plasma and their pharmacokinetic parameters were calculated. The pharmacokinetic behavior of cantide and its metabolites (M1 and M2) after iv gtt administration (8, 16 and 24 mg kg(-1)) in rhesus monkeys were investigated. After iv gtt administration of cantide to rhesus monkeys, cantide in plasma was eliminated rapidly and the terminal elimination half-life (t1/2) was 57.91-77.97 min, the correlation coefficients (r) to the dose of Cmax AUC(o-inf) and AUC(0-t) of the prototype was 0.9918, 0.9568 and 0.9773, respectively. The metabolites of cantide reached the Cmax following cantide immediately and the Cmax of metabolites were lower than that of the prototype. The CL(S) of cantide and its metabolites (M1 and M2) were 1.60-2.19, 5.92-8.58 and 6.07-8.78 mL min(-1) kg(-1), respectively. So, it is concluded that the Cmax of cantide and its metabolites increased with the dose, which is the same as their AUC(0-inf) and AUC(0-t). The CL(S) of metabolites were higher than that of the prototype. The MRT and t1/2 of metabolites in the high dose group increased obviously.
Animals ; Area Under Curve ; Electrophoresis, Capillary ; methods ; Female ; Half-Life ; Infusions, Intravenous ; Macaca mulatta ; Male ; Oligonucleotides, Antisense ; blood ; metabolism ; pharmacokinetics ; Phosphorothioate Oligonucleotides ; blood ; metabolism ; pharmacokinetics ; Solid Phase Extraction